QNTM Quantum Biopharma Ltd.
Price Chart
Executive Summary
Quantum BioPharma disclosed that the FDA placed its lead drug candidate Lucid-MS (for multiple sclerosis) on clinical hold on May 28, 2026, pending additional information. The company is withdrawing previously disclosed timelines for Phase 2 trial initiation and interim data. Additionally, director Dr. Lakshmi P. Kotra resigned effective June 1, 2026. This is a material negative regulatory setback for the company's primary pipeline asset.
Actionable Insight
The clinical hold is a binary event for QNTM given the $34M market cap and Lucid-MS as the lead asset. Watch for the company's response package submission and FDA feedback; the hold duration is unpredictable. The director resignation adds governance uncertainty. Consider the stock at risk of significant downside until the hold is resolved.
Key Facts
- FDA placed IND for Lucid-MS (Lucid-21-302) on clinical hold on May 28, 2026
- Company withdrawing previously disclosed timelines for Phase 2 trial initiation and interim data milestones
- Director Dr. Lakshmi P. Kotra resigned from all positions effective June 1, 2026
- Company believes issues are addressable and plans to submit a response package
- Market cap is $34M — clinical hold on lead asset represents a major binary risk event
Financial Impact
No financial figures reported; clinical hold on lead drug candidate Lucid-MS places the company's primary value driver at risk and delays any potential revenue timeline indefinitely
Risk Factors
- Clinical hold may remain in place for a prolonged period or may not be lifted
- Additional studies or data may be required beyond current scope, increasing cash burn
- Director resignation signals potential internal challenges
- Withdrawn timelines create a valuation vacuum — no near-term catalysts
- Pre-revenue biotech with no approved products; dependent on financing for operations
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001185185-26-002283 |
| Document: qntm6k060226.htm | 0001185185-26-002283 |
| Document: 0001185185-26-002283-index-headers.html | 0001185185-26-002283 |
| Document: 0001185185-26-002283-index.html | 0001185185-26-002283 |
| Document: 0001185185-26-002283.txt | 0001185185-26-002283 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
14d ago
|
6-K
| $5.11 $3.89 | ▲ +23.87% | ▲ +20.91% | $3.64 (+28.77%) |
|
Jun 2, 2026
14d ago
|
6-K
| $5.11 $3.89 | ▼ −23.87% | ▼ −20.91% | $3.64 (−28.77%) |
|
May 18, 2026
29d ago
|
6-K
| $6.27 $7.05 | ▲ +12.44% | ▲ +10.82% | $3.64 (−41.95%) |
|
Apr 22, 2026
7w ago
|
6-K
| $3.35 $4.73 | ▲ +41.05% | ▲ +40.99% | $3.64 (+8.66%) |
|
Apr 22, 2026
7w ago
|
Press Release
| $3.35 $4.73 | ▲ +41.05% | ▲ +40.99% | $3.64 (+8.66%) |
|
Apr 2, 2026
10w ago
|
6-K
| $3.98 $3.53 | ▼ −11.43% | ▼ −15.05% | $3.64 (−8.54%) |
|
Apr 1, 2026
10w ago
|
6-K
| $4.41 $3.27 | ▼ −25.85% | ▼ −29.62% | $3.64 (−17.46%) |
|
Apr 1, 2026
10w ago
|
Press Release
| $4.41 $3.27 | ▼ −25.85% | ▼ −29.62% | $3.64 (−17.46%) |
|
Mar 30, 2026
11w ago
|
Court Ruling
| $4.28 $3.88 | ▼ −9.35% | ▼ −13.65% | $3.64 (−14.95%) |
|
Mar 27, 2026
11w ago
|
6-K
| $4.77 $3.58 | ▼ −24.95% | ▼ −28.81% | $3.64 (−23.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access